Retraction statement: S14G-humanin inhibits Aβ1–42 fibril formation, disaggregates preformed fibrils, and protects against Aβ-induced cytotoxicity in vitro (Peptide Sci., (2013) 19, (159–165) 10.1002/psc.2484);S14G-humanin inhibits Aβ1-42 fibril formation, disaggregates preformed fibrils, and protects against Aβ-induced cytotoxicity in vitro

Journal of Peptide Science

Volumn 19, Issue 3, 2013, Pages 159-165

  Zhang, Wei ^a   Du, Ying ^a   Bai, Miao ^a   Xi, Ye ^a   Li, Zhuyi ^a   Miao, Jianting ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Alzheimer's disease; Amyloid beta protein; Cytotoxicity; Electron microscopy; S14G humanin; Thioflavin T

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; COLLAGEN FIBRIL; HUMANIN; S14G HUMANIN; THIOFLAVINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CONCENTRATION RESPONSE; CYTOTOXICITY; DRUG EFFICACY; FIBER; FLUORESCENCE; IN VITRO STUDY; NEUROPROTECTION; NONHUMAN; PC12 CELL; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN PROCESSING; TRANSMISSION ELECTRON MICROSCOPY;

EID: 84874022077     PISSN: 10752617     EISSN: 10991387     Source Type: Journal    
DOI: 10.1002/psc.2889     Document Type: Erratum

References (50)

1. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2001; 297: 353-356.
2. St George-Hyslop PH, Petit A. Molecular biology and genetics of Alzheimer's disease. C. R. Biol. 2005; 328: 119-130.
3. Tanzi RE, Bertram L. Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective. Cell 2005; 120: 545-555.
4. Lleó A, Greenberg SM, Growdon JH. Current pharmacotherapy for Alzheimer's disease. Annu. Rev. Med. 2006; 57: 513-533.
5. Seltzer B. Cholinesterase inhibitors in the clinical management of Alzheimer's disease: importance of early and persistent treatment. J. Int. Med. Res. 2006; 34: 339-347.
6. Smith M, Wells J, Borrie M. Treatment effect size of memantine therapy in Alzheimer disease and vascular dementia. Alzheimer Dis. Assoc. Disord. 2006; 20: 133-137.
7. McShane R, Areosa Sastre A, Minakaran N. Memantine for dementia. Cochrane Database Syst. Rev. 2006; 19: CD003154.
8. van Marum RJ. Current and future therapy in Alzheimer's disease. Fundam. Clin. Pharmacol. 2008; 22: 265-274.
9. Arakawa T, Kita Y, Niikura T. A rescue factor for Alzheimer's diseases: discovery, activity, structure, and mechanism. Curr. Med. Chem. 2008; 15: 2086-2098.
10. Hashimoto Y, Niikura T, Tajima H, Yasukawa T, Sudo H, Ito Y, Kita Y, Kawasumi M, Kouyama K, Doyu M, Sobue G, Koide T, Tsuji S, Lang J, Kurokawa K, Nishimoto I. A rescue factor abolishing neuronal cell death by a wide spectrum of familial Alzheimer's disease genes and Abeta. Proc. Natl. Acad. Sci. U. S. A. 2001; 98: 6336-6341.
11. Kunesová G, Hlavácek J, Patocka J, Evangelou A, Zikos C, Benaki D, Paravatou-Petsotas M, Pelecanou M, Livaniou E, Slaninova J. The multiple T-maze in vivo testing of the neuroprotective effect of humanin analogues. Peptides 2008; 29 :1982-1987.
12. Niikura T, Tajima H, Kita Y. Neuronal cell death in Alzheimer's disease and a neuroprotective factor, humanin. Curr. Neuropharmacol. 2006; 4: 139-147.
13. Nishimoto I, Matsuoka M, Niikura T. Unravelling the role of Humanin. Trends Mol. Med. 2004; 10: 102-105.
14. Miao J, Zhang W, Yin R, Liu R, Su C, Lei G, Li Z. S14G-Humanin ameliorates Abeta25-35-induced behavioral deficits by reducing neuroinflammatory responses and apoptosis in mice. Neuropeptides 2008; 2: 557-567.
15. Tajima H, Kawasumi M, Chiba T, Yamada M, Yamashita K, Nawa M, Kita Y, Kouyama K, Aiso S, Matsuoka M, Niikura T, Nishimoto I. A humanin derivative, S14G-HN, prevents amyloid-beta-induced memory impairment in mice. J. Neurosci. Res. 2005; 79: 714-723.
16. Zhang W, Miao J, Hao J, Li Z, Xu J, Liu R, Cao F, Wang R, Chen J, Li Z. Protective effect of S14G-humanin against beta-amyloid induced LTP inhibition in mouse hippocampal slices. Peptides 2009; 30: 1197-1202.
17. Guo F, Jing W, Ma CG, Wu MN, Zhang JF, Li XY, Qi JS. [Gly(14)]-humanin rescues long-term potentiation from amyloid beta protein-induced impairment in the rat hippocampal CA1 region in vivo. Synapse 2010; 64: 83-91.
18. Niikura T, Sidahmed E, Hirata-Fukae C, Aisen PS, Matsuoka Y. A humanin derivative reduces amyloid beta accumulation and ameliorates memory deficit in triple transgenic mice. PLoS One 2011; 6: e16259.
19. Zhang W, Zhang W, Li Z, Hao J, Zhang Z, Liu L, Mao N, Miao J, Zhang L. S14G-Humanin improves cognitive deficits and reduces amyloid pathology in the middle-aged APPswe/PS1dE9 mice. Pharmacol. Biochem. Behav. 2011; 100: 361-369.
20. Hao J, Zhang W, Zhang P, Liu R, Liu L, Lei G, Su C, Miao J, Li Z. Abeta20-29 peptide blocking apoE/Abeta interaction reduces full-length Abeta42/40 fibril formation and cytotoxicity in vitro. Neuropeptides 2010; 44: 305-313.
21. Sadowski MJ, Pankiewicz J, Scholtzova H, Mehta PD, Prelli F, Quartermain D, Wisniewski T. Blocking the apolipoprotein E/amyloid-beta interaction as a potential therapeutic approach for Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 2006; 103: 18787-18792.
22. Durairajan SS, Yuan Q, Xie L, Chan WS, Kum WF, Koo I, Liu C, Song Y, Huang JD, Klein WL, Li M. Salvianolic acid B inhibits Abeta fibril formation and disaggregates preformed fibrils and protects against Abeta-induced cytotoxicty. Neurochem. Int. 2008; 52: 741-750.
23. Jana A, Pahan K. Fibrillar amyloid-beta-activated human astroglia kill primary human neurons via neutral sphingomyelinase: implications for Alzheimer's disease. J. Neurosci. 2010; 30: 12676-12689.
24. Hirohata M, Ono K, Takasaki J, Takahashi R, Ikeda T, Morinaga A, Yamada M. Anti-amyloidogenic effects of soybean isoflavones in vitro: fluorescence spectroscopy demonstrating direct binding to Aβ monomers, oligomers and fibrils. Biochim. Biophys. Acta 2012; 1822: 1316-1324.
25. Datki Z, Juhász A, Gálfi M, Soós K, Papp R, Zádori D, Penke B. Method for measuring neurotoxicity of aggregating polypeptides with the MTT assay on differentiated neuroblastoma cells. Brain Res. Bull. 2003; 62: 223-229.
26. Yoshiike Y, Tanemura K, Murayama O, Akagi T, Murayama M, Sato S, Sun X, Tanaka N, Takashima A. New insights on how metals disrupt amyloid beta-aggregation and their effects on amyloid-beta cytotoxicity. J. Biol. Chem. 2001; 276: 32293-32299.
27. Querfurth HW, LaFerla FM. Alzheimer's disease. N. Engl. J. Med. 2010; 362: 329-344.
28. Walsh DM, Selkoe DJ. A beta oligomers-a decade of discovery. J. Neurochem. 2007; 101: 1172-1184.
29. Picone P, Carrotta R, Montana G, Nobile MR, San Biagio PL, Di Carlo M. Abeta oligomers and fibrillar aggregates induce different apoptotic pathways in LAN5 neuroblastoma cell cultures. Biophys. J. 2009; 96: 4200-4211.
30. Cenini G, Cecchi C, Pensalfini A, Bonini SA, Ferrari-Toninelli G, Liguri G, Memo M, Uberti D. Generation of reactive oxygen species by beta amyloid fibrils and oligomers involves different intra/extracellular pathways. Amino Acids 2010; 38: 1101-1106.
31. Tomic JL, Pensalfini A, Head E, Glabe CG. Soluble fibrillar oligomer levels are elevated in Alzheimer's disease brain and correlate with cognitive dysfunction. Neurobiol. Dis. 2009; 35: 352-358.
32. Ohyagi Y Intracellular amyloid beta-protein as a therapeutic target for treating Alzheimer's disease. Curr. Alzheimer Res. 2008; 5: 555-561.
33. Abramowski D, Rabe S, Upadhaya AR, Reichwald J, Danner S, Staab D, Capetillo-Zarate E, Yamaguchi H, Saido TC, Wiederhold KH, Thal DR, Staufenbiel M. Transgenic expression of intraneuronal Aβ42 but not Aβ40 leads to cellular Aβ lesions, degeneration, and functional impairment without typical Alzheimer's disease pathology. J. Neurosci. 2012; 32: 1273-1283.
34. Nath S, Agholme L, Kurudenkandy FR, Granseth B, Marcusson J, Hallbeck M. Spreading of neurodegenerative pathology via neuron-to-neuron transmission of β-amyloid. J. Neurosci. 2012; 32: 8767-8777.
35. Re F, Airoldi C, Zona C, Masserini M, La Ferla B, Quattrocchi N, Nicotra F. Beta amyloid aggregation inhibitors: small molecules as candidate drugs for therapy of Alzheimer's disease. Curr. Med. Chem. 2010; 17: 2990-3006.
36. Galimberti D, Scarpini E. Alzheimer's disease: from pathogenesis to disease-modifying approaches. CNS Neurol. Disord. Drug Targets 2011; 10: 163-174.
37. Frisardi V, Solfrizzi V, Imbimbo PB, Capurso C, D'Introno A, Colacicco AM, Vendemiale G, Seripa D, Pilotto A, Capurso A, Panza F. Towards disease-modifying treatment of Alzheimer's disease: drugs targeting beta-amyloid. Curr. Alzheimer Res. 2010; 7: 40-55.
38. Dasilva KA, Shaw JE, McLaurin J. Amyloid-beta fibrillogenesis: structural insight and therapeutic intervention. Exp. Neurol. 2010; 223: 311-321.
39. Nie Q, Du XG, Geng MY. Small molecule inhibitors of amyloid β peptide aggregation as a potential therapeutic strategy for Alzheimer's disease. Acta Pharmacol. Sin. 2011; 32: 545-551.
40. LeVine H 3rd. Small molecule inhibitors of Abeta assembly. Amyloid 2007; 14: 185-197.
41. Yamin G, Ono K, Inayathullah M, Teplow DB. Amyloid beta-protein assembly as a therapeutic target of Alzheimer's disease. Curr. Pharm. Des. 2008; 14: 3231-3246.
42. Zou P, Ding Y, Sha Y, Hu B, Nie S. Humanin peptides block calcium influx of rat hippocampal neurons by altering fibrogenesis of Abeta(1-40). Peptides 2003; 24:679-685.
43. Naito A, Kawamura I. Solid-state NMR as a method to reveal structure and membrane-interaction of amyloidogenic proteins and peptides. Biochim. Biophys. Acta 2007; 1768:1900-1912.
44. Kirschner DA, Abraham C, Selkoe DJ. X-ray diffraction from intraneuronal paired helical filaments and extraneuronal amyloid fibers in Alzheimer disease indicates cross-beta conformation. Proc. Natl. Acad. Sci. U. S. A. 1986; 83: 503-507.
45. Stromer T, Serpell LC. Structure and morphology of the Alzheimer's amyloid fibril. Microsc. Res. Tech. 2005; 67: 210-217.
46. Maftei M, Tian X, Manea M, Exner TE, Schwanzar D, von Arnim CA, Przybylski M. Interaction structure of the complex between neuroprotective factor humanin and Alzheimer's β-amyloid peptide revealed by affinity mass spectrometry and molecular modeling. J. Pept. Sci. 2012; 18: 373-382.
47. Wang MS, Boddapati S, Sierks MR. Antifibrillizing agents catalyze the formation of unstable intermediate aggregates of beta-amyloid. Biotechnol. Prog. 2010; 26: 1172-1179.
48. Estrada LD, Soto C. Disrupting beta-amyloid aggregation for Alzheimer disease treatment. Curr. Top. Med. Chem. 2007; 7: 115-126.
49. Benaki D, Zikos C, Evangelou A, Livaniou E, Vlassi M, Mikros E, Pelecanou M. Solution structure of Ser14Gly-humanin, a potent rescue factor against neuronal cell death in Alzheimer's disease. Biochem. Biophys. Res. Commun. 2006; 349: 634-642.
50. Zapala B, Kaczyński L, Kieć-Wilk B, Staszel T, Knapp A, Thoresen GH, Wybrańska I, Dembińska-Kieć A. Humanins, the neuroprotective and cytoprotective peptides with antiapoptotic and anti-inflammatory properties. Pharmacol. Rep. 2010; 62: 767-777.